{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:10:04Z","timestamp":1751087404525,"version":"3.41.0"},"reference-count":18,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25019","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T22:07:54Z","timestamp":1751062074000},"page":"140-145","source":"Crossref","is-referenced-by-count":0,"title":["Brentuximab vedotin monotherapy for CD30-positive adult T-cell leukemia\/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells"],"prefix":"10.3960","volume":"65","author":[{"given":"Shun","family":"Ito","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"},{"name":"Division of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Watanabe-Nishimaki","sequence":"additional","affiliation":[{"name":"Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kennosuke","family":"Karube","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Namiki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hamada","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon","family":"Otake","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S\u00e9zary T-cell leukaemia. Nature. 1981; 294: 268-271.","DOI":"10.1038\/294268a0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T\u2010cell leukaemia\u2010lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Katsuya H, Yamanaka T, Ishitsuka K <i>et al.<\/i> Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012; 30: 1635-1640.","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Katsuya H, Ishitsuka K, Utsunomiya A <i>et al.<\/i> Treatment and survival among 1594 patients with ATL. Blood. 2015; 126: 2570-2577.","DOI":"10.1182\/blood-2015-03-632489"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Tsukasaki K, Utsunomiya A, Fukuda H <i>et al.<\/i> VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007; 25: 5458-5464.","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"6","unstructured":"6 Karube K, Takatori M, Sakihama S <i>et al.<\/i> Clinicopathological features of adult T-cell leukemia\/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Blood Adv. 2021; 5: 198-206."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Nakashima M, Yamochi T, Watanabe M <i>et al.<\/i> CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1-infected individuals. Clin Cancer Res. 2018; 24: 5445-5457.","DOI":"10.1158\/1078-0432.CCR-18-0268"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Horwitz S, O\u2019Connor OA, Pro B <i>et al.<\/i> Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019; 393: 229-240.","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Cook LB, Phillips AA. How I treat adult T-cell leukemia\/lymphoma. Blood. 2021; 137: 459-470.","DOI":"10.1182\/blood.2019004045"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Plattel WJ, Bergamasco A, Trinchese F <i>et al.<\/i> Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2021; 62: 3320-3332.","DOI":"10.1080\/10428194.2021.1957865"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Wang Y, Wang Z, Wei C <i>et al.<\/i> Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases. Ann Hematol. 2023; 102: 2973-2975.","DOI":"10.1007\/s00277-023-05390-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan: An Update. Front Microbiol. 2020; 11: 1124.","DOI":"10.3389\/fmicb.2020.01124"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Satou A, Takahara T, Tsuzuki T. Pathological and molecular features of nodal peripheral T-cell lymphomas. Diagnostics (Basel). 2022; 12: 2001.","DOI":"10.3390\/diagnostics12082001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ohshima K, Suzumiya J, Kato A, Tashiro K, Kikuchi M. Clonal HTLV-I-infected CD4+ T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer. 1997; 72: 592-598.","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<592::AID-IJC7>3.0.CO;2-L"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Takeuchi M, Miyoshi H, Semba Y <i>et al.<\/i> Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia\/lymphoma. Haematologica. 2023; 108: 3496-3501.","DOI":"10.3324\/haematol.2023.283163"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Watanabe M, Hatsuse H, Nagao K <i>et al.<\/i> CD30 stimulation induces multinucleation and chromosomal instability in HTLV-1-infected cell lines. Int J Hematol. 2023; 118: 75-87.","DOI":"10.1007\/s12185-023-03583-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Horwitz S, O\u2019Connor OA, Pro B <i>et al.<\/i> The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022; 33: 288-298.","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Baba Y, Sakai H, Kabasawa N, Harada H. Successful Treatment of an Aggressive Adult T-cell Leukemia\/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy. Intern Med. 2023; 62: 613-616.","DOI":"10.2169\/internalmedicine.9812-22"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:30Z","timestamp":1751085930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_25019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25019","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25019"}}